Inspired by Patients
Supported by Healthcare Workers, Payers and Pharma
Our ENZYPAD technology is bringing the lab to the patient, enabling diagnostic-based telemedicine and fast response in case of life-threatening bleeding.Takeda and Enzyre to develop diagnostic device
The ENZYPAD enables real near patient blood coagulation analysis, with the measured data being effortlessly made available to the treating physician irrespective of his/her physical location.
The ENZYPAD technology includes (a) a painless, easy to use blood sampling device; (b) a test specific single use microfluidic cartridge (“ENZYCARD”) that includes all necessary reagents and controls; and (c) a small hands-on re-useable processor (“ENZYPAD”) that enables the reagent flow, processes the test results and transfers those immediately to the cloud. The processor is controlled by an App on a mobile phone.
By transferring the data to the cloud, they can be made available to anyone with the appropriate authorization who can use them to efficiently manage the therapy of the patient.
The ENZYPAD technology uses proprietary innovative latent luciferin-protected peptide substrates to determine the activity of specific enzymes in the coagulation cascade. The enzymatic activity is directly proportional to the number of photons generated in the reaction chamber. These chemiluminescent signals are counted using highly sensitive optical sensors. One ENZYCARD (microfluidic cartridge) can run up to 16 individual reactions simultaneously, providing the health care professional with direct access to all the relevant data. All this is done starting from less than 100µL of whole blood collected though the specially developed blood collection device.
Our team has over 60 years of experience in diagnostic development and world class expertise in blood coagulation. We are proud to have a Hemophilia A patient amongst our staff. His inspiration is fundamental in our dedication to make the right product.
Enzyre is now preparing to raise €10M in its Series A investment round. The proceeds will be used to (a) finalize the development of the ENZYPAD en ENZYCARD Hemophilia A, (b) manufacture the portable instrument & disposable, and (c) perform studies to obtain regulatory approval in EU & US. The product will be commercialized worldwide through our pharma partner. Interested candidate investors are encouraged to contact us at firstname.lastname@example.org.Get involved